

Comparison of the Effects of Latanoprost and Bimatoprost

Journal of Glaucoma

17, 398-402

DOI: [10.1097/ijg.0b013e31815d784c](https://doi.org/10.1097/ijg.0b013e31815d784c)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Central corneal thickness in subjects with glaucoma and in normal individuals (with or without) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74	1.8	17
2	Update and commentary on the pro-drug bimatoprost and a putative α -prostanamide receptor TM . Expert Review of Ophthalmology, 2009, 4, 477-489.	0.6	11
3	Central Corneal Thickness During Treatment With Travoprost 0.004% in Glaucoma Patients. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 459-462.	1.4	22
4	The Effect of Prostaglandin Analogs and Prostanamide on Central Corneal Thickness. Journal of Ocular Pharmacology and Therapeutics, 2009, 25, 51-54.	1.4	36
6	Intraocular pressure profile during the modified diurnal tension curve using Goldman applanation tonometry and dynamic contour tonometry. Journal of Ocular Biology, Diseases, and Informatics, 2009, 2, 29-32.	0.2	5
8	Bimatoprost. Drugs and Aging, 2009, 26, 1049-1071.	2.7	20
9	Applanation Tonometry Versus Dynamic Contour Tonometry in Eyes Treated With Latanoprost. Journal of Glaucoma, 2010, 19, 194-198.	1.6	14
10	Goldmann Applanation Tonometry and Dynamic Contour Tonometry After Treatment With Prostaglandin Analog/Prostanamide. Journal of Glaucoma, 2010, 19, 346.	1.6	4
11	Differences Between Applanation Tonometry and Dynamic Contour Tonometry in Prostaglandin Analogue-treated Eyes. Journal of Glaucoma, 2010, 19, 347.	1.6	2
12	Effect of Latanoprost on the Expression of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinase 1 on the Ocular Surface. JAMA Ophthalmology, 2010, 128, 466.	2.4	51
13	Effect of Acute Increases of Intraocular Pressure on Corneal Pachymetry in Eyes Treated with Travoprost: An Animal Study. Current Eye Research, 2011, 36, 1014-1019.	1.5	9
14	Preservative Use in Topical Glaucoma Medications. Ocular Surface, 2011, 9, 140-158.	4.4	37
15	The Comparison of the Effects of Latanoprost, Travoprost, and Bimatoprost on Central Corneal Thickness. Cornea, 2011, 30, 861-864.	1.7	52
16	Long-Term Effect of Latanoprost on Central Corneal Thickness in Normal Tension Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2011, 27, 73-76.	1.4	14
18	The influence of central corneal thickness on response to topical prostaglandin analogue therapy. Canadian Journal of Ophthalmology, 2012, 47, 51-54.	0.7	8
19	Randomized crossover study of latanoprost and travoprost in eyes with open-angle glaucoma. Graefe's Archive for Clinical and Experimental Ophthalmology, 2012, 250, 123-129.	1.9	13
20	Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clinical and Experimental Ophthalmology, 2013, 41, 348-354.	2.6	29
21	Central Corneal Thickness and Glaucoma Treatment: An Italian Multicenter Cross-Sectional Study. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 469-473.	1.4	13

#	ARTICLE	IF	CITATIONS
22	Therapeutic uses of prostaglandin F2 \pm analogues in ocular disease and novel synthetic strategies. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 109-121.	1.9	27
23	Effect of Tafluprost 0.0015% on Central Corneal Thickness in Patients With Primary Open-angle Glaucoma. Current Eye Research, 2013, 38, 977-982.	1.5	20
24	Factors Influencing Intermethod Agreement Between Goldmann Applanation, Pascal Dynamic Contour, and Ocular Response Analyzer Tonometry. Journal of Glaucoma, 2013, 22, 487-495.	1.6	12
25	Effect of Latanoprost on Central Corneal Thickness in Unilateral Normal-Tension Glaucoma. Journal of Ocular Pharmacology and Therapeutics, 2013, 29, 335-338.	1.4	13
26	Effect of Timolol on Central Corneal Thickness. European Journal of Ophthalmology, 2013, 23, 784-788.	1.3	13
27	Cornea and Glaucoma. , 2013, , .		3
28	Effects of Long-Term Topical Prostaglandin Therapy on Central Corneal Thickness. Journal of Ocular Pharmacology and Therapeutics, 2014, 30, 440-444.	1.4	34
29	Switching efficacy on intraocular pressure from latanoprost to bimatoprost in eyes with open angle glaucoma: implication to the changes of central corneal thickness. Japanese Journal of Ophthalmology, 2014, 58, 423-428.	1.9	4
30	Decreased keratocyte density and central corneal thickness in primary open-angle glaucoma patients undergoing treatment with topical prostaglandin analogues. Indian Journal of Ophthalmology, 2015, 63, 15.	1.1	12
31	Changes in Corneal Biomechanical Properties after Long-Term Topical Prostaglandin Therapy. PLoS ONE, 2016, 11, e0155527.	2.5	46
32	The Matrix Metalloproteinase 9 Point-of-Care Test in Dry Eye. Ocular Surface, 2016, 14, 189-195.	4.4	92
33	Comparison of Central Corneal Thickness Measured by Swept-source Optical Coherence Tomography and Ultrasound Pachymetry. Journal of Korean Ophthalmological Society, 2017, 58, 276.	0.2	2
34	Effect of manual eyelid manipulation on intraocular pressure measurement by rebound tonometry. British Journal of Ophthalmology, 2018, 102, 1515-1519.	3.9	9
35	The Glaucoma Italian Pediatric Study (GIPSy): 3-Year Results. Journal of Glaucoma, 2018, 27, 856-863.	1.6	14
36	Pharmacokinetics, Safety, and Intraocular Pressure-Lowering Profile of Omidenepag Isopropyl, a Selective, Nonprostaglandin, Prostanoid EP2 Receptor Agonist, in Healthy Japanese and Caucasian Volunteers (Phase I Study). Journal of Ocular Pharmacology and Therapeutics, 2019, 35, 542-550.	1.4	20
37	The effect of topical latanoprost on corneal clarity; 1-year prospective study. Cutaneous and Ocular Toxicology, 2019, 38, 253-257.	1.3	8
38	Ocular Surface Changes in Prostaglandin Analogue-Treated Patients. Journal of Ophthalmology, 2019, 2019, 1-7.	1.3	10
39	The changes of corneal biomechanical properties with long-term treatment of prostaglandin analogue measured by Corvis ST. BMC Ophthalmology, 2020, 20, 422.	1.4	15

#	ARTICLE	IF	CITATIONS
40	Omidenepag Isopropyl Versus Latanoprost in Primary Open-Angle Glaucoma and Ocular Hypertension. <i>American Journal of Ophthalmology</i> , 2020, 220, 53-63.	3.3	67
41	The Glaucoma Italian Pediatric Study (GIPSy): The Long-term Effect of Topical Latanoprost on Central Corneal Thickness. <i>Journal of Glaucoma</i> , 2020, 29, 441-447.	1.6	2
42	Matrix Metalloproteinases and Glaucoma Treatment. <i>Journal of Ocular Pharmacology and Therapeutics</i> , 2020, 36, 208-228.	1.4	70
43	Do topical antiglaucoma drugs affect the cornea?. <i>European Journal of Ophthalmology</i> , 2021, , 112067212110169.	1.3	4
44	Central Corneal Thickness and Glaucoma. <i>Journal of Current Glaucoma Practice</i> , 2009, 3, 1-6.	0.5	0
45	Biomecánica en el glaucoma. , 2014, , 205-219.		0
46	Cytotoxicity of pilocarpine to human corneal stromal cells and its underlying cytotoxic mechanisms. <i>International Journal of Ophthalmology</i> , 2016, 9, 505-11.	1.1	5
47	Effect of long-term topical latanoprost medication on conjunctival thickness in patients with glaucoma. <i>International Journal of Ophthalmology</i> , 2018, 11, 1158-1162.	1.1	3
48	Central Corneal Thickness as Measured by Spectral-Domain Optical Coherence Tomography in Glaucomatous and Non-Glaucomatous Eyes. <i>Journal of Medical Sciences and Health</i> , 2020, 05, 13-18.	0.1	0
49	Topical latanoprost does not cause macular thickening after uncomplicated cataract surgery. <i>Journal of Ophthalmic and Vision Research</i> , 2012, 7, 289-94.	1.0	5
50	Effect of prostaglandin analogues on central corneal thickness in patients with glaucoma: A systematic review and meta-analysis with trial sequential analysis. <i>Indian Journal of Ophthalmology</i> , 2022, 70, 1502.	1.1	10
51	Comparison of corneal, endothelial, and anterior segment parameters in eyes with and without pigment dispersion. <i>Photodiagnosis and Photodynamic Therapy</i> , 2022, 40, 103161.	2.6	0
52	The Effect of Prostaglandin Analogs on Central Corneal Thickness of Patients with Glaucoma or Ocular Hypertension: A Systematic Review. <i>Ophthalmic Research</i> , 2023, 66, 431-444.	1.9	0
53	Effects of topical prostaglandin therapy on corneal layers thickness in primary open-angle glaucoma patients using anterior segment optical coherence tomography. <i>International Ophthalmology</i> , 0, , .	1.4	1